Back to Search
Start Over
Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection.
- Source :
-
Frontiers in immunology [Front Immunol] 2020 Jul 29; Vol. 11, pp. 1673. Date of Electronic Publication: 2020 Jul 29 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Respiratory syncytial virus (RSV) remains the most common cause of lower respiratory tract infections in children worldwide. Development of a vaccine has been hindered by the risk of developing enhanced respiratory disease (ERD) upon natural exposure to the virus. Generation of higher quality neutralizing antibodies with stabilized pre-fusion F protein antigens has been proposed as a strategy to prevent ERD. We sought to test whether there was evidence of ERD in naïve BALB/c mice immunized with an unadjuvanted, stabilized pre-fusion F protein, and challenged with RSV line 19. We further sought to determine the extent to which formulation with a Th2-biased (alum) or a more Th1/Th2-balanced (Advax-SM) adjuvant influenced cellular responses and lung pathology. When exposed to RSV, mice immunized with pre-fusion F protein alone (PreF) exhibited increased airway eosinophilia and mucus accumulation. This was further exacerbated by formulation of PreF with Alum (aluminum hydroxide). Conversely, formulation of PreF with a Th1/Th2-balanced adjuvant, Advax-SM, not only suppressed RSV viral replication, but also inhibited airway eosinophilia and mucus accumulation. This was associated with lower numbers of lung innate lymphocyte cells (ILC2s) and CD4+ T cells producing IL-5+ or IL-13+ and increased IFNγ+ CD4+ and CD8+ T cells, in addition to RSV F-specific CD8+ T cells. These data suggest that in the absence of preimmunity, stabilized PreF antigens may still be associated with aberrant Th2 responses that induce lung pathology in response to RSV infection, and can be prevented by formulation with more Th1/Th2-balanced adjuvants that enhance CD4+ and CD8+ IFNγ+ T cell responses. This may support the use of stabilized PreF antigens with Th1/Th2-balanced adjuvants like, Advax-SM, as safer alternatives to alum in RSV vaccine candidates.<br /> (Copyright © 2020 Eichinger, Kosanovich, Gidwani, Zomback, Lipp, Perkins, Oury, Petrovsky, Marshall, Yondola and Empey.)
- Subjects :
- Animals
Antibodies, Neutralizing blood
Antibodies, Viral blood
Cytokines immunology
Cytokines metabolism
Disease Models, Animal
Female
Immunity, Humoral drug effects
Immunization
Immunogenicity, Vaccine drug effects
Lung immunology
Lung pathology
Lung virology
Mice, Inbred BALB C
Respiratory Syncytial Virus Infections immunology
Respiratory Syncytial Virus Infections pathology
Respiratory Syncytial Virus Infections virology
Respiratory Syncytial Viruses immunology
Respiratory Syncytial Viruses pathogenicity
Th1-Th2 Balance drug effects
Th2 Cells immunology
Th2 Cells metabolism
Th2 Cells virology
Adjuvants, Immunologic pharmacology
Aluminum Hydroxide pharmacology
Lung drug effects
Respiratory Syncytial Virus Infections prevention & control
Respiratory Syncytial Virus Vaccines pharmacology
Respiratory Syncytial Viruses drug effects
Th2 Cells drug effects
Viral Fusion Proteins pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 32849580
- Full Text :
- https://doi.org/10.3389/fimmu.2020.01673